Triamcinolone Injection for Cochlear Implant Magnet Adherence Issues.
Journal
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
ISSN: 1537-4505
Titre abrégé: Otol Neurotol
Pays: United States
ID NLM: 100961504
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
pmc-release:
01
09
2024
medline:
18
8
2023
pubmed:
8
8
2023
entrez:
8
8
2023
Statut:
ppublish
Résumé
To evaluate the effectiveness of triamcinolone injections in treating external magnet displacement in cochlear implant (CI) patients with adhesions problems of their processor. We present seven CI patients with magnet adhesion issues who presented to our tertiary care neurotology clinic. None of the patients had a history of head trauma, postimplant MRI, or surgery in the head and neck other than the cochlear implantation. Triamcinolone 40 mg/mL injected subcutaneously at the CI magnet site. Reduction of scalp thickness and successful magnet retention. Our cohort consisted of seven patients (eight implant sites) of which five were overweight or obese. The temporoparietal scalp thickness measured on preoperative CT scans varied between 8.4 and 15.9 mm. Initial conservative measures such as hair shaving at the magnet site, using a headband, and increasing magnet strength failed in all patients. After receiving triamcinolone injections at the CI receiver site, six out of seven patients (seven out of eight CI sites) were able to use their processor again without the need for a headband for an average of 9.55 hours/day. The average number of injections required for each patient was 2.57 (SD = 2.18), median (range) = 1 (1-7). One patient required a flap thinning surgery but showed no improvement even after flap thinning. None of the patients showed skin irritation, breakdown, ulceration, necrosis, or magnet exposure during follow-up period. The significant improvement in CI retention shows that triamcinolone injections are effective in making the subcutaneous tissue thinner and allowing magnet retention.
Identifiants
pubmed: 37550870
doi: 10.1097/MAO.0000000000003974
pii: 00129492-990000000-00362
pmc: PMC10529445
mid: NIHMS1911024
doi:
Substances chimiques
Triamcinolone
1ZK20VI6TY
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e572-e576Subventions
Organisme : NCATS NIH HHS
ID : TL1 TR001415
Pays : United States
Informations de copyright
Copyright © 2023, Otology & Neurotology, Inc.
Déclaration de conflit d'intérêts
Conflict of interest: Hamid R. Djalilian holds equity in MindSet Technologies, Elinava Technologies, and Cactus Medical LLC. He is a consultant to NXT Biomedical.
Références
Cochlear Implants Int. 2007 Sep;8(3):123-47
pubmed: 17854099
Aesthetic Plast Surg. 2021 Dec;45(6):3037-3044
pubmed: 34184094
Otolaryngol Clin North Am. 2012 Feb;45(1):221-48
pubmed: 22115692
Arch Plast Surg. 2014 Nov;41(6):620-9
pubmed: 25396172
Otol Neurotol. 2010 Jan;31(1):88-93
pubmed: 19924015
J Otol. 2022 Apr;17(2):72-77
pubmed: 35949548
Indian Dermatol Online J. 2022 Mar 03;13(2):199-206
pubmed: 35287395
Eur Arch Otorhinolaryngol. 2016 Dec;273(12):4175-4183
pubmed: 27245752
J Craniofac Surg. 2017 Nov;28(8):e781-e785
pubmed: 28938330
Burns. 2021 Aug;47(5):987-998
pubmed: 33814214
Cochlear Implants Int. 2021 Mar;22(2):80-84
pubmed: 32993474
Otolaryngol Clin North Am. 2020 Feb;53(1):87-102
pubmed: 31677740
JAMA Otolaryngol Head Neck Surg. 2013 May;139(5):446-53
pubmed: 23681026